- Vienna '18
- ESCRS Player
- On Demand
- ESCRS iLearn
- ESCRS YO's
First Author: A.Khafagy EGYPT
Co Author(s): T. Belal
Back to previous
The purpose of this study is to evaluate the efficacy of intracameral Ranibizumab injection with subsequent Mitomycin C augmented trabeculectomy in managing neovascular glaucoma.
Ophthalmology department, Kasr El-Aini Hospital and Petrol Medical Center, Cairo, Egypt
This is a prospective, interventional study that included 15 eyes of 15 patients with neovascular. In all eyes, intracameral injection of Ranibizumab (0.5 mg) was done and subsequent Mitomycin C augmented trabeculectomy was performed within 4 weeks from the injection. All patients were followed for 6 months.
13 eyes (86.7%) had complete regression of iris neovascularization after one intracameral Ranibizumab injection and 2 eyes (13.3%) after a second injection. 8 eyes (53.3%) achieved complete success (if the intraocular pressure was between 10-21 mmHg) without topical antiglaucoma medications, 6 eyes (40%) had qualified success (if the intraocular pressure was within the same range) but with topical antiglaucoma medications and failure occurred in one eye (6.7%) (if the intraocular pressure was above 21mmHg) despite the use of topical antiglaucoma medications.
Intracameral Ranibizumab injection with subsequent Mitomycin C augmented trabeculectomy is an effective surgical technique in controlling intraocular pressure in eyes with neovascular glaucoma.